How to curb drug price increases is expected to remain a topic of debate in 2018, though the policies with the most support among lawmakers and administration officials target pharmacy benefit managers instead of drug makers. At least one more congressional hearing on the topic is expected in 2018, states are asking CMS to allow closed formularies in Medicaid, the agency is considering testing value-based reimbursement approaches and the Federal Trade Commission is looking into what causes drug price hikes...